Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 7Gynecologic 6Gastrointestinal 6Other hematologic neoplasm 5Lymphoid 5Thoracic 3Myeloid 3NET 2Genitourinary 2Endocrine 2Classical hematology 2CNS 2Dermatologic 1Breast 1

Conditions

Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 485Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
3-aminopyridine-2-carboxaldehyde thiosemicarbazone × Breast × Clear all
NCT00095888 2013-01-16

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
68 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡